Cancer risk in long-term users of valproate: A population-based case-control study

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1714-1719

  Hallas, Jesper ^a   Friis, Søren ^b   Bjerrum, Lars ^a   Støvring, Henrik ^a   Narverud, Sverre Flatabø ^a   Heyerdahl, Thomas ^a   Grønbæk, Kirsten ^c   Andersen, Morten ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HISTONE DEACETYLASE; LITHIUM; OXCARBAZEPINE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CHEMOPROPHYLAXIS; CHILD; CONTROLLED STUDY; DENMARK; DOSE RESPONSE; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NEWBORN; POPULATION RESEARCH; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SCHOOL CHILD;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CASE-CONTROL STUDIES; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; RISK FACTORS; TIME; VALPROIC ACID;

EID: 67449090572     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0646     Document Type: Article

References (33)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784 (Pubitemid 44348499)
2. Shabbeer S, Kortenhorst SQ, Kachhap S, Galloway N, Rodriguez R, Carducci MA. Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 2007;67:1099-1110 (Pubitemid 46983339)
3. Jawed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES, Niles LP. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 2007;560:17-22. (Pubitemid 46320399)
4. Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 2007;105:297-309. (Pubitemid 47596448)
5. Blaheta RA, Michaelis M, Driever PH, Cinatl J, Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25:383-397
6. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005;128:7-17. (Pubitemid 40073649)
7. Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002;26:495-502. (Pubitemid 34251096)
8. Cruz-Hernandez E, Perez-Cardenas E, Contreras-Paredes A, et al. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J 2007;4:18. (Pubitemid 46391967)
9. Blaheta RA, Michaelis M, Natsheh I, et al. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 2007;96:1699-1706 (Pubitemid 46847201)
10. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997;44:535-539 (Pubitemid 27505373)
11. Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. Avaluable source of data for modern health sciences. Dan Med Bull 1999;46:263-268
12. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-448 (Pubitemid 27382061)
13. http://www.whocc.no/atcddd/. Accessed 2009 April 6.
14. Rothman KJ. Epidemiology, an introduction. Oxford: Oxford Press; 2002. p. 76-77
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
16. Rothman KJ. Epidemiology, an introduction. Oxford: Oxford Press; 2002. p. 194.
17. http://www.sst.dk/Informatik-og-sundhedsdata/Udgivelser-af- sundhedsstatistik/Kraeft.aspx? Accessed 2009 April 6.
18. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308 (Pubitemid 47523148)
19. Münster P, Marchion D, Bicaku E, et al. Phase Itrial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-1985 (Pubitemid 46972780)
20. Elliott JO, Lu B, Shneker B, Charyton C, Layne Moore J. Comorbidity, health screening, and quality of life among persons with a history of epilepsy. Epilepsy Behav 2009;14:125-129
21. Elliott JO, Lu B, Moore JL, McAuley JW, Long L. Exercise, diet, health behaviors, and risk factors among persons with epilepsy based on the California Health Interview Survey, 2005. Epilepsy Behav 2008;13:307-315
22. Kobau R, DiIorio CA, Price PH, et al. Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: Behavioral Risk Factor Surveillance System, 2002. Epilepsy Behav 2004;5:358-366
23. Tetsche MS, Nørgaard M, Skriver MV, Andersen ES, Lash TL, Sørensen HT. Accuracy of ovarian cancer ICD-10 diagnosis in a Danish population-based hospital discharge registry. Eur J Gynaecol Oncol 2005;26:266-270 (Pubitemid 40874037)
24. Nørgaard M, Skriver MV, Gregersen H, Pedersen G, Schønheyder HC, Sørensen HT. The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry. Eur J Cancer Prev 2005;14:201-206 (Pubitemid 40780442)
25. Sørensen HT, Larsen BO. A population-based Danish data resource with possible high validity in pharmacoepidemiological research. J Med Syst 1994;18:33-38 (Pubitemid 24177302)
26. Csizmadl I, Collet J-P, Boivin JF. Bias and confounding in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology. 4th edition. West Sussex: Wiley and Sons; p. 791-810.
27. Krämer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteosomal degradation of HDAC2. EMBO J 2003;22:3411-3420 (Pubitemid 36834871)
28. Xia Q, Sung J, Chowdhury W, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006;66:723744. (Pubitemid 44197704)
29. Cinatl J, Jr., Kotchetkov R, Blaheta RA, Driever PH, Vogel JU, Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-α. Int J Oncol 2002;20:97-106.
30. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978 (Pubitemid 34062289)
31. Milutinovic S, D'Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007;28:560-571 (Pubitemid 46523352)
32. Williams DC, Jr., Massey GV, Russell EC, Riley RS, Ben-Ezra J. Translocation positive acute myeloid leukemia associated with valproic acid therapy. Pediatr Blood Cancer 2008;50:641-643 (Pubitemid 351155843)
33. Coyle TE, Bair AK, Stein C, Vajpayee N, Mehdi S, Wright J. Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis? Am J Hematol 2005;78:256-260